Adjuvant Nivolumab + Ipilimumab Lacks Efficacy for Localized RCC
Trial did not meet primary efficacy end point of disease-free survival in patients with localized RCC at high risk for postnephrectomy relapse
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.